NASDAQ:BIOS - BioScrip Stock Price, Price Target & More

$2.67 -0.03 (-1.11 %)
(As of 04/24/2018 01:02 AM ET)
Previous Close$2.67
Today's Range$2.6450 - $2.74
52-Week Range$1.45 - $3.39
Volume188,507 shs
Average Volume892,404 shs
Market Capitalization$344.78 million
P/E Ratio-6.07
Dividend YieldN/A
Beta0.11

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200

Debt

Debt-to-Equity Ratio-5.65%
Current Ratio1.79%
Quick Ratio1.42%

Price-To-Earnings

Trailing P/E Ratio-6.07
Forward P/E Ratio-9.54
P/E GrowthN/A

Sales & Book Value

Annual Sales$817.19 million
Price / Sales0.42
Cash FlowN/A
Price / CashN/A
Book Value($0.66) per share
Price / Book-4.05

Profitability

EPS (Most Recent Fiscal Year)($0.44)
Net Income$-64,190,000.00
Net Margins-9.45%
Return on EquityN/A
Return on Assets-9.35%

Miscellaneous

Employees2,154
Outstanding Shares127,700,000

How to Become a New Pot Stock Millionaire

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip, Inc. (NASDAQ:BIOS) released its quarterly earnings results on Thursday, March, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07. The firm had revenue of $182.50 million for the quarter, compared to analyst estimates of $171.35 million. The business's revenue for the quarter was down 24.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) earnings per share. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for BioScrip.

What price target have analysts set for BIOS?

4 brokers have issued 1-year price targets for BioScrip's shares. Their predictions range from $3.25 to $4.00. On average, they anticipate BioScrip's stock price to reach $3.5625 in the next twelve months. View Analyst Ratings for BioScrip.

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 51)
  • Mr. Alex Schott, Sr. VP of Strategic Operations & Interim Chief Accounting Officer (Age 48)
  • Ms. Jody Kepler, Sr. VP, Chief Compliance Officer & Privacy Officer (Age 48)

Has BioScrip been receiving favorable news coverage?

Press coverage about BIOS stock has been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioScrip earned a daily sentiment score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 45.68 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are BioScrip's major shareholders?

BioScrip's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ARDSLEY ADVISORY PARTNERS (0.07%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $2.67.

How big of a company is BioScrip?

BioScrip has a market capitalization of $344.78 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 950, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (BIOS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioScrip (NASDAQ:BIOS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for BioScrip in the last 12 months. Their average twelve-month price target is $3.5625, suggesting that the stock has a possible upside of 33.43%. The high price target for BIOS is $4.00 and the low price target for BIOS is $3.25. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.5625$3.5625$3.8333$3.9375
Price Target Upside: 33.43% upside37.28% upside44.65% upside36.25% upside

BioScrip (NASDAQ:BIOS) Consensus Price Target History

Price Target History for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018SunTrust BanksReiterated RatingBuy$3.25MediumView Rating Details
3/8/2018Craig HallumReiterated RatingBuy$3.50MediumView Rating Details
8/10/2017Jefferies GroupReiterated RatingBuy$3.00 -> $4.00HighView Rating Details
6/26/2017Barrington ResearchBoost Price TargetOutperform$3.50HighView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

BioScrip (NASDAQ:BIOS) Earnings History and Estimates Chart

Earnings by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.10)($0.06)($0.08)
Q2 20182($0.07)($0.05)($0.06)
Q3 20182($0.06)($0.03)($0.05)
Q4 20182($0.01)$0.00($0.01)
Q1 20191($0.04)($0.04)($0.04)
Q2 20191($0.03)($0.03)($0.03)
Q3 20191($0.02)($0.02)($0.02)

BioScrip (NASDAQ BIOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.10)N/AView Earnings Details
3/8/2018Q4 2017($0.08)($0.15)$171.35 million$182.50 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.10)($0.12)$202.91 million$198.70 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.10)($0.11)$220.05 million$218.11 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
11/6/2013Q3 2013$0.01$0.02$205.09 million$208.88 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
11/2/2010Q3 2010$0.09$0.05ViewN/AView Earnings Details
7/30/2010Q2 2010$0.09$0.07ViewN/AView Earnings Details
4/30/2010Q1 2010$0.07($0.01)ViewN/AView Earnings Details
2/26/2010Q4 2009$0.10$0.03ViewN/AView Earnings Details
10/30/2009Q3 2009$0.10$0.14ViewN/AView Earnings Details
7/30/2009Q2 2009$0.06$0.11ViewN/AView Earnings Details
4/30/2009Q1 2009$0.04$0.08ViewN/AView Earnings Details
3/3/2009Q4 2008$0.05$0.09ViewN/AView Earnings Details
11/4/2008Q3 2008$0.05$0.06ViewN/AView Earnings Details
7/31/2008Q2 2008$0.03$0.04ViewN/AView Earnings Details
5/2/2008Q1 2008$0.05($0.01)ViewN/AView Earnings Details
3/4/2008Q4 2007$0.04$0.06ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioScrip (NASDAQ:BIOS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioScrip (NASDAQ BIOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 84.29%
Insider Trading History for BioScrip (NASDAQ:BIOS)
Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ BIOS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2017Daniel E GreenleafCEOBuy15,000$2.03$30,450.0031,000View SEC Filing  
11/9/2017Stephen DeitschCFOBuy10,000$2.03$20,300.0010,000View SEC Filing  
9/15/2017Michael G BronfeinDirectorSell27,000$2.69$72,630.00129,669View SEC Filing  
9/7/2017Coliseum Capital Management, LDirectorSell2,846,941$2.93$8,341,537.13View SEC Filing  
8/17/2017Coliseum Capital Management, LDirectorSell886,478$3.08$2,730,352.24View SEC Filing  
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.0022,628View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.0016,000View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.0084,000View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.0042,500View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.0030,000View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.0015,000View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.002,580View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.0071,360View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.785,088View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioScrip (NASDAQ BIOS) News Headlines

Source:
DateHeadline
Comparing Chemed (CHE) & BioScrip (BIOS)Comparing Chemed (CHE) & BioScrip (BIOS)
www.americanbankingnews.com - April 23 at 9:30 AM
BioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $170.23 MillionBioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $170.23 Million
www.americanbankingnews.com - April 21 at 2:34 AM
Head to Head Survey: BioScrip (BIOS) & Amedisys Home Health and Hospice Care (AMED)Head to Head Survey: BioScrip (BIOS) & Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - April 20 at 9:22 PM
-$0.11 Earnings Per Share Expected for BioScrip, Inc. (BIOS) This Quarter-$0.11 Earnings Per Share Expected for BioScrip, Inc. (BIOS) This Quarter
www.americanbankingnews.com - April 19 at 5:20 PM
Analyzing Chemed (CHE) & BioScrip (BIOS)Analyzing Chemed (CHE) & BioScrip (BIOS)
www.americanbankingnews.com - April 19 at 1:23 AM
Pre-Market Technical Scan on Healthcare Equities -- Heron Therapeutics, Immune Pharma, Johnson & Johnson, and ...Pre-Market Technical Scan on Healthcare Equities -- Heron Therapeutics, Immune Pharma, Johnson & Johnson, and ...
www.prnewswire.com - April 18 at 8:11 AM
BioScrip (BIOS) Rating Lowered to Buy at BidaskClubBioScrip (BIOS) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM
BioScrip (BIOS) Cut to Sell at ValuEngineBioScrip (BIOS) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 14 at 2:30 PM
BioScrip Inc’s (NASDAQ:BIOS) Earnings Dropped -62.14%, Did Its Industry Show Weakness Too?BioScrip Inc’s (NASDAQ:BIOS) Earnings Dropped -62.14%, Did Its Industry Show Weakness Too?
finance.yahoo.com - April 11 at 8:23 AM
BioScrip (BIOS) Lifted to "Buy" at SunTrust BanksBioScrip (BIOS) Lifted to "Buy" at SunTrust Banks
www.americanbankingnews.com - April 11 at 12:11 AM
BioScrip (BIOS) Raised to Hold at ValuEngineBioScrip (BIOS) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 10 at 5:02 PM
Reviewing BioScrip (BIOS) and Civitas Solutions (CIVI)Reviewing BioScrip (BIOS) and Civitas Solutions (CIVI)
www.americanbankingnews.com - April 9 at 11:19 PM
Why Is BioScrip (BIOS) Down 5.6% Since its Last Earnings Report?Why Is BioScrip (BIOS) Down 5.6% Since its Last Earnings Report?
finance.yahoo.com - April 9 at 8:13 AM
Analyzing BioScrip (BIOS) and Amedisys Home Health and Hospice Care (AMED)Analyzing BioScrip (BIOS) and Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - April 8 at 5:06 PM
BioScrip Inc (BIOS) Given Average Rating of "Hold" by AnalystsBioScrip Inc (BIOS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 8 at 3:36 AM
Blog Exposure - Addus Homecare Completes Acquisition of Arcadia Home Care & Staffing for $18.5 MillionBlog Exposure - Addus Homecare Completes Acquisition of Arcadia Home Care & Staffing for $18.5 Million
finance.yahoo.com - April 4 at 8:14 AM
BioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $170.23 MillionBioScrip Inc (BIOS) Expected to Announce Quarterly Sales of $170.23 Million
www.americanbankingnews.com - April 4 at 2:30 AM
 Analysts Anticipate BioScrip Inc (BIOS) Will Post Earnings of -$0.11 Per Share Analysts Anticipate BioScrip Inc (BIOS) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 2 at 7:12 PM
BioScrip (BIOS) Upgraded by ValuEngine to "Sell"BioScrip (BIOS) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 1 at 12:08 AM
BioScrip (BIOS) Upgraded to "Buy" by BidaskClubBioScrip (BIOS) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM
BioScrip Timely Files Annual Form 10-K, Concludes Accounting Review and Provides Update on Immaterial Financial Statement CorrectionsBioScrip Timely Files Annual Form 10-K, Concludes Accounting Review and Provides Update on Immaterial Financial Statement Corrections
finance.yahoo.com - March 26 at 8:16 AM
Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc ... - PR Newswire (press release)Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:41 AM
New Research Coverage Highlights Real Goods Solar, LivePerson, Manhattan Associates, Natus Medical, BioScrip, and FBL Financial Group -- Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Real Goods Solar, LivePerson, Manhattan Associates, Natus Medical, BioScrip, and FBL Financial Group -- Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - March 21 at 8:41 AM
What does BioScrip Inc’s (NASDAQ:BIOS) Balance Sheet Tell Us About Its Future?What does BioScrip Inc’s (NASDAQ:BIOS) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - March 19 at 5:22 PM
BioScrips Dull 2017 Earnings a Woe, Core Business RobustBioScrip's Dull 2017 Earnings a Woe, Core Business Robust
finance.yahoo.com - March 16 at 6:34 PM
Zacks: Brokerages Expect BioScrip Inc (BIOS) to Announce -$0.11 EPSZacks: Brokerages Expect BioScrip Inc (BIOS) to Announce -$0.11 EPS
www.americanbankingnews.com - March 16 at 3:52 PM
BioScrip Provides Update on Annual Form 10-K Filing Status ... - Business Wire (press release)BioScrip Provides Update on Annual Form 10-K Filing Status ... - Business Wire (press release)
www.businesswire.com - March 16 at 8:13 AM
Why BioScrip (BIOS) Could Be Positioned for a Slump - NasdaqWhy BioScrip (BIOS) Could Be Positioned for a Slump - Nasdaq
www.nasdaq.com - March 15 at 8:10 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud ... - Business Wire (press release)INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud ... - Business Wire (press release)
www.businesswire.com - March 15 at 8:10 AM
BioScrip Inc (BIOS) Given Average Recommendation of "Hold" by AnalystsBioScrip Inc (BIOS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 14 at 3:42 AM
BioScrip (BIOS) Downgraded by Zacks Investment ResearchBioScrip (BIOS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 13 at 11:49 AM
BioScrip (BIOS) Loss Widens in Q4, 18 View Holds Promise - NasdaqBioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise - Nasdaq
www.nasdaq.com - March 13 at 8:17 AM
BioScrip (BIOS) Loss Widens in Q4, 18 View Holds PromiseBioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise
www.msn.com - March 12 at 6:44 PM
BioScrip (BIOS) Loss Widens in Q4, '18 View Holds PromiseBioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise
finance.yahoo.com - March 12 at 6:44 PM
BioScrip (BIOS) Downgraded by BidaskClubBioScrip (BIOS) Downgraded by BidaskClub
www.americanbankingnews.com - March 10 at 7:10 PM
Glancy Prongay & Murray LLP Announces Investigation on Behalf of ... - Business Wire (press release)Glancy Prongay & Murray LLP Announces Investigation on Behalf of ... - Business Wire (press release)
www.businesswire.com - March 10 at 8:16 AM
BioScrip (BIOS) Releases Quarterly  Earnings Results, Beats Estimates By $0.06 EPSBioScrip (BIOS) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - March 9 at 10:35 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioScrip, Inc. - BIOS - PR Newswire (press release)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioScrip, Inc. - BIOS - PR Newswire (press release)
www.prnewswire.com - March 9 at 8:13 AM
BioScrip accounting review identifies internal control deficiencies and material weakness - MarketWatchBioScrip accounting review identifies 'internal control deficiencies' and 'material weakness' - MarketWatch
www.marketwatch.com - March 9 at 8:13 AM
BioScrip, Incs (BIOS) CEO Daniel Greenleaf on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaBioScrip, Inc's (BIOS) CEO Daniel Greenleaf on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:13 AM
Milberg Tadler Phillips Grossman LLP Announces Investigation of ... - PR Newswire (press release)Milberg Tadler Phillips Grossman LLP Announces Investigation of ... - PR Newswire (press release)
www.prnewswire.com - March 9 at 8:13 AM
Craig Hallum Reiterates Buy Rating for BioScrip (BIOS)Craig Hallum Reiterates Buy Rating for BioScrip (BIOS)
www.americanbankingnews.com - March 8 at 8:19 PM
BioScrip (BIOS) Receives "Buy" Rating from SunTrust BanksBioScrip (BIOS) Receives "Buy" Rating from SunTrust Banks
www.americanbankingnews.com - March 8 at 8:16 PM
Denver medical company discovers potential financial statement errorsDenver medical company discovers 'potential financial statement errors'
www.bizjournals.com - March 8 at 6:52 PM
BioScrip accounting review identifies internal control deficiencies and material weaknessBioScrip accounting review identifies 'internal control deficiencies' and 'material weakness'
finance.yahoo.com - March 8 at 6:52 PM
BIOSCRIP INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In BioScrip Inc. To Contact The FirmBIOSCRIP INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In BioScrip Inc. To Contact The Firm
finance.yahoo.com - March 8 at 6:52 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioScrip, Inc. - BIOSSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioScrip, Inc. - BIOS
finance.yahoo.com - March 8 at 6:52 PM
Milberg Tadler Phillips Grossman LLP Announces Investigation of BioScrip, Inc.Milberg Tadler Phillips Grossman LLP Announces Investigation of BioScrip, Inc.
finance.yahoo.com - March 8 at 6:52 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of BioScrip, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of BioScrip, Inc.
finance.yahoo.com - March 8 at 6:52 PM
BioScrip, Inc. (BIOS) Investigated By Block & Leviton LLP For Violations Of The Federal Securities LawsBioScrip, Inc. (BIOS) Investigated By Block & Leviton LLP For Violations Of The Federal Securities Laws
www.prnewswire.com - March 8 at 2:23 PM

SEC Filings

BioScrip (NASDAQ:BIOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioScrip (NASDAQ:BIOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioScrip (NASDAQ BIOS) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.